Patients with cancer often experience significant financial toxicity due to the high direct and indirect costs associated with their care. These costs include the treatments themselves, as well as a decline in productivity and expenses related to commuting to and from appointments. During the COVID-19 pandemic, telemedicine use grew exponentially, as it allowed many aspects of oncology care to continue while limiting patients’ and healthcare workers’ exposure to the coronavirus.
At the 12th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2022, held October 19-21, in New York City, a panel of experts from Upstream Partners discussed the current state of value-based agreements (VBAs) in pharma and what lies ahead. The session was moderated by Burt Zweigenhaft, PhD, DLitt, Executive Director and Co-Founder of AVBCC.
Latest AAM Report Shows Generic and Biosimilar Drugs Saved US Healthcare System $338 Million in 2020
On September 21, 2021, the Association for Accessible Medicines (AAM), the trade association of generic and biosimilar manufacturers, released topline findings from its forthcoming 2021 U.S. Generic & Biosimilar Medicines Savings Report highlighting the value of generic and biosimilar drugs.
Policymakers are once again focusing attention on proposals to lower prescription drug costs.
As biosimilars are being used more and more in cancer treatment, it is increasingly important that navigators and financial advocates be familiar not only with how they work but also how patients with cancer should go about paying for them, according to Angie Santiago, AA, CRCS-I, lead financial advocate at the Sidney Kimmel Cancer Center/Jefferson Health.
The use of a screening method followed by a financial toxicity intervention that involves navigators, pharmacists, and financial counselors demonstrated significantly improved quality of life for patients with hematologic malignancies, said lead investigator Thomas Greg Knight, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, at ASH 2020.
An analysis of the Value Framework of the American Society of Clinical Oncology (ASCO) shows that the Net Health Benefit score of cancer drugs continues to evolve over time after their FDA approval, based on data presented at the ASCO 2020 virtual annual meeting. This analysis showed a substantial change in more than 25% of cancer drugs in their Net Health Benefit 3 years after their initial approval.
As the complexity of cancer care continues to evolve, adhering to evidence-based treatment guidelines is a growing challenge for oncologists. The use of clinical decision support tools within the electronic health record (EHR) system can boost provider compliance and drive quality improvement, according to data presented at the ASCO 2020 virtual annual meeting.
Germline Analysis Proves Valuable in Selecting Targetable Treatments for Patients with Advanced Cancer
New research highlights the importance of germline analysis in the identification of germline alterations for cancer treatment. According to a large analysis presented at the ASCO 2020 virtual annual meeting, nearly 9% of patients with advanced cancer harbor a targetable germline variant.
Cemiplimab-rwlc (Libtayo), a new PD-1 inhibitor, has transformed the treatment of advanced cutaneous squamous-cell carcinoma (CSCC), significantly extending survival for patients.
Page 1 of 2
Results 1 - 10 of 17
Results 1 - 10 of 17